Santaris, Silence Therapeutics, Oxford, Sigma, Alnylam

Jul 05, 2007

Premium

Santaris Receives Grant to Develop miRNA-Targeting Drug

Santaris Pharma said this week that it has received a €1.35 million ($1.8 million) grant from the Danish National Advanced Technology Foundation to develop SPC3649, a locked nucleic acid-based drug that targets the microRNA miR-122.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Sharing, But Kinda Sorta

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

This Week in Science

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

Structural Biologist Leads India's CSIR

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

Upward of One Hundred

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Featured White Papers

iPSC & CRISPR/Cas9 Technologies Enable Precise & Controlled Physiologically Relevant Disease Modeling for Basic & Applied Research

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Nov

05

Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov

15

Featured Webinar

Next-Generation Platforms for Strain Optimization: Reducing the Cost and Time for Commercializing Novel Biological Molecules

This webinar will discuss how Amyris, a biotechnology company that develops renewable products for a broad range of applications and industries, uses large-scale microbial engineering to support its manufacturing processes.

Main menu